at a glance
Harmonisation | Influenza
01 March 2015 to 28 February 2022
Sclavo Vaccines Association
IMI Innovative Medicines Initiative, European Union and EFPIA
14 Mio Euro
Standardization and Development of Assays for Assessment of Influenza Vaccines Correlates of Protection
The human influenza virus is the causative agent of one of the most important infectious diseases in the world, causing frequent (seasonal) epidemics as well as pandemics, both of which cause significant morbidity and mortality worldwide. Influenza virus infects all age groups but children and adults over the age of 65 are most at risk of severe morbidity and mortality. Vaccination is recommended for these age groups. Vaccination remains the most effective method to control seasonal infections and the most important strategy to prepare for a possible pandemic. Despite the development and licensure of influenza vaccines along with clinical evidence of their ability to protect against influenza, the potential correlates of protection induced by these vaccines are still not fully elucidated
The availability of a tool-box of standardised, validated serological assays for human influenza vaccines, agreed and used by key parties in the private and in the public sector will have tremendous impact on the R&D process globally, and will pave the way for future investigation and definition of correlates of protection for these vaccines.
Abbott (Netherlands); Artemis Bio-Support B.V. (Netherlands); AstraZeneca AB (Sweden); Biomedical Primate Research Centre (BPRC) (Netherlands); Erasmus Universitair Medisch Centrum Rotterdam (EUMCR) (Netherlands); European Medicines Agency (EMA) (Netherlands); European Vaccine Initiative (EVI) (Germany); Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico (Italy); GlaxoSmithKline (GSK) (Belgium); Istituto Superiore di Sanità (Italy); Janssen Vaccines and Prevention B.V. (Netherlands); MHRA-Department of Health (UK); Paul-Ehrlich-Institut (Germany); QUINTEN (France); Sanofi Pasteur (France); Sclavo Vaccines Association (Italy); Seqirus (Switzerland); University of Oxford (UK); Università degli Studi di Siena (UNISI) (Italy); Universiteit Gen Universitetet i Bergen (Norway); University of Perugia (Italy); University of Surrey (UK).
This project has received funding from Innovative Medicines Initiative Joint Undertaking under grant agreement No 115672, resources of which are composed of financial contribution from the European Union’s Seventh Framework Programme (FP/2007-2013) and EFPIA companies’ in kind contribution.